6533b7dbfe1ef96bd1270a63

RESEARCH PRODUCT

Erratum: Melanoma Unknown Primary Brain Metastasis Treatment With ECHO-7 Oncolytic Virus Rigvir: A Case Report

Pēteris AlbertsSergejs Isajevs

subject

Cancer ResearchCase ReportBlood–brain barrierblood–brain barrierlcsh:RC254-282Text miningmelanoma brain metastasisRigvir®medicineECHO-7 virusoncolytic virusbusiness.industryMelanomaintranasalEcho (computing)medicine.diseaselcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensOncolytic virusmedicine.anatomical_structureOncologymelanoma unknown primaryCancer researchUnknown primaryErratumbusinessBrain metastasis

description

Melanoma is considered an aggressive malignancy with a tendency of forming metastasis in the brain. Less than 10% of all melanoma cases present with unknown primary tumor location. This diagnose is yet to be fully understood, because there are only theoretical assumptions about the nature of the disease. Melanoma brain metastases have many severe side effects and, unfortunately, any disease related to the brain has limited therapeutic options due to the blood–brain barrier. The course of the disease after a treatment course is complicated to predict, and it is difficult to obtain long-lasting remission. In this report, we describe a female patient with unknown primary melanoma brain metastasis treated with the oncolytic ECHO-7 virus Rigvir® after brain surgery. The patient has been stable, as monitored by magnetic resonance imaging, for more than 3.8 years with ongoing therapy. The median expected overall survival from the time of diagnosis is approximately 5 months. Additional positive effect could have been gained from use of the intranasal administration route, which is considered effective due to the direct anatomical connection between the nasal cavity and the central nervous system. However, further studies are required to fully understand this mode of drug administration.

10.3389/fonc.2018.00172http://europepmc.org/articles/PMC5968167